Angiogenic signaling pathways and anti-angiogenic therapy for cancer | Signal Transduction and Targeted Therapy
metastatic hormone sensitive prostate cancer :: Article Creator New Data For NUBEQA® Build On Safety And Efficacy Results Across Subgroups Of Patients With Metastatic Hormone-Sensitive Prostate Cancer WHIPPANY, N.J., February 13, 2025--(BUSINESS WIRE)--New subgroup data from the investigational Phase III ARANOTE trial show NUBEQA® (darolutamide) plus androgen-deprivation therapy (ADT) improved radiological progression-free survival (rPFS) in patients with high and low-volume metastatic hormone sensitive (mHSPC) by 40% (hazard ratio [HR] 0.60; 95% confidence interval [CI] 0.44-0.80) and 70% (HR 0.30; 95% CI 0.15-0.60) respectively, compared to placebo plus ADT. The overall incidence of adverse events was low, with incidence similar in the high and low-volume subgroups and consistent with the overall population. The full results were presented during the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2025 Congress. NUBEQ...